News

TMCnet

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified ...

HCW Biologics Inc.: HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified effic ...
The Daily Cardinal

UW professor aims to use personalized vaccines to prevent cancer recurrence

Quanyin Hu, a professor in the University of Wisconsin-Madison School of Pharmacy, spoke to The Daily Cardinal about his ...

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid ...
University of Geneva

Tamburini Jérôme

Jérôme Tamburini studied medicine in Paris (Université Paris Descartes) and specialised in clinical haematology. He holds a ...
EurekAlert!

$15.7 million in new grants awarded to scientists at Wertheim UF Scripps

These grants highlight The Wertheim UF Scripps Institute’s unique expertise in areas that include neuroscience, immunology, ...
EurekAlert!

Internationally recognized malaria researcher Stefan Kappe, Ph.D., appointed new director of the UM School of Medicine's Center for Vaccine Development and Global Health

University of Maryland School of Medicine Dean, Mark T. Gladwin, MD, announced today the appointment of distinguished parasitologist and immunologist Stefan Kappe, PhD, to be the new Director of the ...

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, ...
PharmiWeb

āshibio Reports Promising Preclinical Data for Two First-in-Class Antibodies Targeting Debilitating Bone Disorders at ASBMR Meeting

Oral presentation highlights potential utility of vantictumab for treatment of autosomal dominant osteopetrosis type 2 (ADO2) –– Poster documents benefit of MMP9 inhibition in a mouse model of ...